ENCBS418CBB / cell line
Summary
- Status
- released
- Term name
- SK-N-SH
- Term ID
- EFO:0003072
- Summary
- Homo sapiens SK-N-SH cell line genetically modified (insertion) using CRISPR targeting H. sapiens ZFP3 treated with 6 μM all-trans-retinoic acid for 48 hours
- Separated from biosample
- ENCBS353QOO
- Parent of biosamples
- ENCBS792ZHS, ENCBS639AKM
Attribution
ENCODE4 project
- Lab
- Michael Snyder, Stanford
- Award PI
- Michael Snyder, Stanford
- Submitted by
- Nathaniel Watson
- Source
- Michael Snyder
- Project
- ENCODE
- External resources
- Aliases
- michael-snyder:pB-2609, michael-snyder:pB-eGFP-ZFP3 SK-N-SH
Treatment details
- Treatment
- 6 μM all-trans-retinoic acid (CHEBI:15367) for 48 hours
- Type
- chemical
- Purpose
- activation
Genetic modifications
Accession | Category | Purpose | Method | Nucleic acid delivery method | Site |
|---|---|---|---|---|---|
| ENCGM026QJV | insertion | tagging | CRISPR |
|
Donor information
- Status
- released
- Accession
- ENCDO000ABD
- Aliases
- encode:donor of SK-N-SH, bradley-bernstein:Donor of SK-N-SH cells, encode:donor of SH-SY5Y
- Species
- Homo sapiens
- Life stage
- child
- Age
- 4 years
- Sex
- female
- Health status
- Metastatic neuroblastoma from bone marrow
- External resources
- References
Documents
growth protocol
Description: Cell growth protocol for SK-N-SH cells (version 1).
- Submitted by
- Nathaniel Watson
- Lab
- Michael Snyder, Stanford
- Grant
- UM1HG009442
transfection protocol
Description excerpt: SK-N-SH transfection protocol - Version 1 (Replicates split at T-75 stage, 200…
- Description
- SK-N-SH transfection protocol - Version 1 (Replicates split at T-75 stage, 200 µg/ml G418)
- Submitted by
- Nathaniel Watson
- Lab
- Michael Snyder, Stanford
- Grant
- U54HG006996
treatment protocol
Description: RA treatment protocol for SK-N-SH cells (version 1).
- Submitted by
- Nathaniel Watson
- Lab
- Michael Snyder, Stanford
- Grant
- U54HG006996